Efforts to understand the molecular basis of human immunodeficiency virus (HIV) envelope glycoprotein function have been hampered by the inability to generate sufficient quantities of homogeneous material. We now report on the high level expression, purification, and characterization of soluble HIV gp140 ectodomain proteins in Chinese hamster ovary-Lec3.2.8.1 cells. Gel filtration and analytical ultracentrifugation show that the uncleaved ADA strain-derived gp140 proteins are trimeric without further modification required to maintain oligomers. These spike proteins are native as judged by soluble CD4 (sCD4) (K D ‫؍‬ 1-2 nM) and monoclonal antibody binding studies using surface plasmon resonance. CD4 ligation induces conformational change in the trimer, exposing the chemokine receptor binding site as assessed by 17b monoclonal antibody reactivity. Lack of anti-cooperativity in sCD4-ADA trimer interaction distinct from that observed with sCD4-SIV mac32H implies quaternary structural differences in ground states of their respective spike proteins.
Efforts to understand the molecular basis of human immunodeficiency virus (HIV) envelope glycoprotein function have been hampered by the inability to generate sufficient quantities of homogeneous material. We now report on the high level expression, purification, and characterization of soluble HIV gp140 ectodomain proteins in Chinese hamster ovary-Lec3.2.8.1 cells. Gel filtration and analytical ultracentrifugation show that the uncleaved ADA strain-derived gp140 proteins are trimeric without further modification required to maintain oligomers. These spike proteins are native as judged by soluble CD4 (sCD4) (K D ‫؍‬ 1-2 nM) and monoclonal antibody binding studies using surface plasmon resonance. CD4 ligation induces conformational change in the trimer, exposing the chemokine receptor binding site as assessed by 17b monoclonal antibody reactivity. Lack of anti-cooperativity in sCD4-ADA trimer interaction distinct from that observed with sCD4-SIV mac32H implies quaternary structural differences in ground states of their respective spike proteins.
Human immunodeficiency virus (HIV),
1 a member of the retroviridae family, is the pathogenic agent for AIDS (1) (2) (3) . HIV-1 and HIV-2 are the two major serotypes of HIV. Simian immunodeficiency virus (SIV) is also classified as a member of the same family of retroviruses and causes AIDS-like symptoms in macaques, thereby providing a good model for HIV infection in humans (4, 5) . The envelope protein of each HIV/ SIV is synthesized first as a gp160 polyprotein precursor in the endoplasmic reticulum. Post-translational modification processes include glycosylation, oligomerization, and cleavage into gp120 and gp41 by a furin-like enzyme in the Golgi network, with subsequent transport to the surface of the infected cells (6 -8) . The cleaved gp120 and gp41 remain nonconvalently associated with one another and are incorporated into the budding virions.
HIV infection requires the serial interaction of its envelope proteins with both a cellular receptor and co-receptor (9 -13) . Hence, after gp120 on the virus surface binds with its receptor, CD4, on the T cell, a conformational change occurs within the envelope inducing gp120 to bind to cellular chemokine coreceptors, typically CCR5 or CXCR4 (see Refs. 14 -16 and references therein). This second binding event triggers gp41 fusion between the virus and the cell membranes with additional conformational transitions permitting viral genome entry into the infected cells. There are two proteolytic cleavage sites within gp160 necessary for its processing to generate the mature gp120 and gp41 subunits (17) (18) (19) . Mutagenesis analysis showed that replacement of one or more basic amino acids within each site can abolish cleavage and prevent viral infectivity (17) (18) (19) (20) (21) . Apparently, certain of the aforementioned conformational changes fail to occur when the gp120 and gp41 components are tethered together by a covalent linkage.
The propensity for HIV envelope proteins to undergo oligomerization has been reported in previous studies. For example, mammalian cell-expressed gp160 as well as various truncation variants (22) or gp140 (a gp160 ectodomain lacking gp41 transmembrane and cytoplasmic segments) (23, 24) were shown to represent mixtures of monomers, dimers, and high ordered oligomers. Likewise, gp140s of three primary macrophage tropic HIV-1 isolates expressed in BHK-1 cells consisted of heterogeneous oligomers (25) . Soluble gp120 produced in mammalian cells using recombinant vaccinia virus expression generated a mixture of monomers plus dimers (26) . A stable HIV gp140 trimer was obtained using protein engineering, substantially modifying the envelope by introducing cysteines to create intersubunit disulfide bonds, eliminating gp120/gp41 cleavage sites and adding GCN4 trimeric helices (27, 28) . In contrast, a soluble trimeric SIV gp140 was expressed in both insect and mammalian cells by simple disruption of 1°and 2°g p120/gp41 cleavage sites alone (29) . So far, no equivalent version of a soluble trimeric HIV gp140 protein has been reported.
The three-dimensional structure of HIV or SIV gp41 reveals that the gp41 ectodomain is a trimer (30 -34) . The gp41 ectodomain comprises a fusion peptide, an N-terminal ␣-helical segment, a glycosylated loop region, a C-terminal ␣-helical segment, and a short, tryptophan-rich membrane linker. The N-terminal helix of each gp41 subunit forms a central parallel trimeric coiled-coil, whereas the C-terminal helix packs against this core in an antiparallel manner to create a six-helix bundle in the postfusion state. Based upon this result, the structure of gp160 was predicted to be a trimer as well. The crystal struc-ture of a monomeric gp120 core, albeit with variable loop deletions and truncation of both N-and C termini, has been determined in complex with CD4 and an anti-gp120 mAb 17b Fab fragment (15) . While extremely important, this structure of the gp120 monomer includes only 60% of gp120 residues and represents the structure of the remaining gp120 after conformational change has been induced by CD4 binding. The structure of gp120 prior to CD4 binding remains unknown, although the pre-CD4 contacted envelope state might represent the most critical structural information for design of fusion inhibitors or the development of protective anti-HIV vaccines. In this regard, a detailed structural understanding of the intact HIV envelope oligomer is a worthwhile goal.
We report here the expression and purification of stable trimeric gp140 of the macrophage-tropic, CCR5-dependent ADA strain of HIV (35, 36) and an ADA/SIV chimera produced in a Lec3.2.8.1 derivative of Chinese hamster ovary (CHO) cells. Both gp140 proteins are secreted into culture supernatants in 4 -5 mg/liter quantities and are trimeric as assessed by analytical ultracentrifugation. The recombinant envelopes are correctly folded based upon CD analysis, reactivity with mAbs, and nanomolar sCD4 binding activity. In contrast to SIV gp140, which shows weaker binding than its monomeric gp120 counterpart, ADA gp140 and ADA/SIV gp140 chimeras bind sCD4 with affinities comparable with the ADA gp120 monomer. The implications of these differences and future potential to investigate HIV envelope glycoprotein trimers in structural terms are discussed.
EXPERIMENTAL PROCEDURES
gp140 Expression Constructs-The pEE14-GS vector (37) containing a Kozak sequence and encoding the tissue plasminogen activator (tPA) leader peptide in lieu of the endogenous viral sequence upstream of the mature gp140 coding sequence was used for all expression constructs. A stop codon was incorporated at the C terminus of the truncated gp41 ectodomain. The pEE14-ADA140 construct contained HIV-1 ADA gp140 coding sequence truncated after Lys 632 (numbered beginning from the first amino acid residue of the mature ADA envelope protein). Briefly, PCR-1, consisting of a Kozak cassette, the tPA leader sequence, and ADA gp120 mature coding sequence, was amplified by Taq DNA polymerase (Roche Molecular Biochemicals) using a pair of amplimers (5-GCTCTAGAAGGGACGCTGTGAAGCAATC-3Ј and 5Ј-CACAAAGA-CCCCTCTTTTTTCTCTCTGCACCAC-3Ј) with pEE14-ADA120 as a template, itself derived by PCR from P009, which contains the HIV-1 ADA cDNA (36) . 2 PCR-2, which contains truncated ADA gp41 coding sequence, was amplified by a pair of primers (5Ј-AGACCTGGGGGAG-GAGATATGAGGG-3Ј and 5Ј-CCGGAATTCTCACTTATCTAATG-3Ј) using the same P009 plasmid template (36) . Both PCR-1 and PCR-2 were cloned into the pCR2.1 vector (Invitrogen) to create pCR-1 and pCR-2. After DNA sequencing, pCR-1 and pCR-2 were digested with XbaI plus MunI or MunI plus EcoRI, respectively. The digested fragments were gel-purified and ligated into the XbaI/EcoRI double-digested pEE14-GS vector at XbaI and EcoRI cloning sites to generate the recombinant expression plasmid pEE14-ADA140.
The HIV/SIV chimeric gp140, which fuses the HIV-1 ADA gp120 mature coding sequence to a truncated SIV Mac 32H gp41 sequence was expressed in pEE14-ADA/SIV140. The SIV gp41 is truncated at Ser 626 (numbers starting from the first amino acid residue of the mature ADA gp120). To amplify the SIV gp41 ectodomain-encoding fragment, PCR-3 was generated by a pair of primers (5Ј-AGAGAAAAAAGAGGGGTCTT-TGTGCTAGGGTTC-3Ј and 5Ј-CCGGAATTCTCAGCT ATTCAACTTT-TGTAATTCATAC-3Ј) using pSIV-M as template (29) . PCR-4 was created using a pair of primers (5Ј-AGACCTGGGGGAGGAGATATGAGG-G-3Ј and 5Ј-CCGGAATTCTCAGCTATTCAACTTTTGTAATTCATAC-3Ј) and PCR-1 and PCR-3 as templates, fusing a segment of the HIV-1 gp120 C terminus with the truncated SIV gp41. The resulting PCR-4 was cloned into pCR2.1 vector as well to generate pCR-4 and sequenced. pCR-1 and pCR-4 were digested with XbaI plus MunI and MunI plus EcoRI, respectively, and the two resulting DNA fragments were then cloned into XbaI/EcoRI double-digested pEE14-GS to generate the expression plasmid pEE14-ADA/SIV140 (Fig. 1) .
To introduce a mutation in the gp160 primary cleavage site in pEE14-ADA140, the QuickChange site-directed mutagenesis method (Stratagene) employing Pfu polymerase was employed. Briefly, two mutagenesis primers (5Ј-GTGGTGCAGAGAGAAAAAAGCGCAGTGG-GAACGATAGGAGC-3Ј and 5Ј-GCTCCTATCGTTCCCACTGCGCTTT-TTTCTCTCTGCACCAC-3Ј) were used to convert Arg 477 to Ser
477
, extending nicked, circular PCR DNA with pCR-1 as a template. Following PCR, the products were treated with DpnI so that the parental DNA template would be digested. After transformation, the mutant doublestranded DNA plasmid, pCR-1m, was created. Subsequently, the digested pCR-1m (XbaI and MunI) and pCR-2 (MunI and EcoRI) were ligated into XbaI/EcoRI double-digested pEE14-GS to generate the expression vector pEE14-ADA140C1. All of the above constructs were verified by DNA restriction digest analysis and DNA sequencing.
Establishment of Stable gp140 Expression Cell Lines-Stable envelope-expressing CHO-Lec3.2.8.1 cell lines were established as previously described (38) using constructs of pEE14-ADA140, pEE14-ADA/ SIV140, and pEE14-ADA140C1. Briefly, 10 g of plasmid DNA was transfected into the CHO-Lec3.2.8.1 cells using the calcium phosphate precipitation method (Transfection MBS Mammalian Transfection Kit; Stratagene). Under the selection pressure of 25 M methionine sulfoximine in GMEM culture media (Life Technologies, Inc.), clones with the highest expression level of secreted gp140 were selected by enzymelinked immunosorbent assays (ELISA). For ELISA, Immulon plates (Dynatech Laboratory Inc.) were coated with 1A3 mAb (mouse mAb produced against HIV-1 SF-2 gp120 and mapping to the V3 loop of both gp120 SF2 and gp120 ADA ) at a concentration of 4 g/ml in PBS at 4°C overnight. After blocking with PBS containing 1% bovine serum albumin at room temperature for 2 h, 50 l of culture supernatant of each transfected clone was added and incubated overnight at 4°C. Following washes with PBS plus 0.1% bovine serum albumin, 0.2 g/ml biotinylated 16F10 mAb (mouse mAb raised against HIV-1 ADA gp120 reactive with an epitope distinct from that of the 1A3 mAb) was applied at 4°C for 1.5 h. Plates were washed extensively and developed by peroxidase-conjugated streptavidin (Sigma). The highest expressing clones were selected and rescreened again. The protein products of selected clones were confirmed by immunoprecipitation using 1A3 mAb GammaBind Plus Sepharose (Amersham Pharmacia Biotech) and further verified by N-terminal amino acid sequencing (DFCI Molecular Biology Core Facility).
gp140 Production and Purification-Large scale production of soluble gp140 was carried out as previously described in 175-cm 2 flasks (Falcon) using confluent cultures with 4 mM sodium butyrate induction for 6 days (38) . To prevent protease cleavage, a mixture of protease inhibitors including leupeptin (0.5 g/ml), chymostatin (0.5 g/ml), antipain (0.5 g/ml), pepstatin A (0.5 g/ml), trypsin inhibitor (0.02 g/ml), and phenylmethylsulfonyl fluoride (0.25 mM) was added to the postproduction supernatants. After centrifugation and subsequent filtration through a Corning filter (0.22 m), the soluble gp140 protein in 2-3 liters of culture supernatant was purified through a 1A3 mAb affinity column (5-ml beads) created by cross-linking GammaBind Plus Sepharose with 1A3 mAb at a concentration of 5 mg/ml using dimethyl pimelimidate (Pierce). The supernatants were loaded onto the affinity column at a speed of 0.5 ml/min, and the bound gp140 was eluted using 0.5 M acetic acid at pH 3.0 and immediately neutralized to pH 7.2 by the addition of 1 M Tris, pH 9.0. Fractions that contained the gp140 protein were pooled, concentrated to 2 ml, and further purified by gel filtration chromatography using a Superdex 200 column (1.6 ϫ 60 cm) (Amersham Pharmacia Biotech) equilibrated in PBS on FPLC (Amersham Pharmacia Biotech).
Circular Dichroism Spectroscopy-The CD spectra were collected on an Aviv circular dichroism spectrometer model 62DS at 25°C. The concentrations of purified trimeric gp140 ADAC1 and gp140 ADA/SIV proteins were each 0.35 mg/ml in PBS. The molar ellipticity () was monitored as the average of 12 scans with 0.5-nm bandwidth and 1.0-nm wavelength increments from 200 to 260 nm. The resulting spectra were corrected according to the base line by using PBS buffer alone.
Analytical Ultracentrifugation-The affinity-purified and sized gp140 ADAC1 and gp140 ADA/SIV proteins in PBS were analyzed by centrifugation at speeds of 6000 and 8000 rpm on a Beckman XL-A analytical ultracentrifugation at 4°C. The concentrations of both proteins were 0.19 and 0.35 mg/ml, respectively, with the data fitted to a singlespecies model. All glycans from CHO-Lec3.2.8.1 cells expressing gp140 were calculated according to the composition GlcNAc 2 -Man 5 based on prior mass spectroscopy determination (39) and with the assumption that all of the potential glycosylation sites are occupied. The collected data of both protein sample sets were processed and calculated according to Laue et al. (40) .
Protein Determination-Protein concentrations were determined by spectrophotometry at 280 nm using specific extinction coefficient factors of 0.60 (gp140 ADA and gp140 ADAC1 ), 0.63 (gp140 ADA/SIV ), 0.72 (gp120 ADA ), 0.71 (intact mAb and Fab fragments), and 0.71 (sCD4), respectively. These factors were calculated by the method of Gill and von Hippel (41) based on the tryptophan, tyrosine, and cysteine contents of each protein. The results agree well with parallel determination made using quantitative amino acid analysis (data not shown).
mAb Purification and Fab Fragment Generation-mAbs were purified as previously described using GammaBind Sepharose (38) . Each antibody was digested with immobilized papain (Pierce) overnight at 37°C, and the undigested antibody and the Fc fragment were separated from the Fab fragment using a protein A kit (Pierce) according to the manufacturer's instructions. The binding buffer was removed by desalting with a Sepharose G-25 column (75 ml). The purity of the Fab fragment was checked by both reducing and nonreducing SDS-PAGE.
Binding of the Purified Trimeric gp140 to mAbs and Soluble CD4 (sCD4)-A mixture of purified trimeric gp140 ADAC1 envelope plus antibody Fab fragments (1A3, 16F10, or 1A3 plus 16F10 at a molar envelope/Fab ratio of 1:4) was incubated at 4°C for 2 h. The resulting complexes were then individually purified by gel filtration chromatography on an analytical Superdex 200 column (Amersham Pharmacia Biotech), and fractions were analyzed by SDS-PAGE. For gp140 ADA/SIV , the purified trimeric protein was mixed with 1A3 Fab fragment and 9G3 (mAb against SIV mac32H gp41) Fab fragment (63) or both 1A3 and 9G3 Fab fragments and analyzed by gel filtration chromatography and SDS-PAGE. sCD4 (the human 4 domain CD4 protein expressed in CHO cells and purified as described) (43) was also mixed with both trimeric gp140 proteins, and binding was similarly analyzed.
Kinetics Analysis of sCD4 Interaction with gp120 and gp140 Proteins by Surface Plasmon Resonance-A BIAcore 1000 instrument (BIAcore) was employed in all of the experiments with binding analyses performed at 25°C in HBS buffer (150 mM NaCl, 3.4 mM EDTA, 0.005% surfactant P-20, 10 mM Hepes, pH 7.4). Envelope proteins were individually coupled to the Sensor Chip CM5 (Biacore) surface using standard amine coupling procedures. For trimeric gp140 ADAC1 and gp140 ADA/ SIV, the immobilization levels were 2800 -3000 RU (response units), whereas for monomeric gp120 the level was 900 -1000 RU. Association and dissociation were measured by passing serial dilutions of sCD4 (20 -50 nM) over each ligand surface at a flow rate of 20 -50 l/min. The sensor chip surface was regenerated between each cycle by an 18-s pulse of 50 mM HCl at a flow rate of 20 l/min. Identical injections over control surfaces (bovine serum albumin) were subtracted from the data for kinetics analysis. BIAevolution 3.0 software (BIAcore) was used for data analysis. Kinetic data fitting was performed using a Langmuir 1:1 binding model.
Analysis of the Binding Interaction between 17b mAb and Envelope Proteins in the Presence or
Absence of sCD4 -To assess envelope conformational change induced by sCD4 binding, the 17b mAb (human neutralizing mAb against HIV, recognizing a CD4-induced epitope on gp120) (44) was coupled (500 -1000 RU) to the Sensor Chip CM5 surface using standard amine coupling procedures on a BIAcore 1000 instrument (BIAcore). Association rates were measured by passing serial dilutions of different envelope proteins with or without sCD4 at a flow rate of 20 -50 l/min at 25°C in HBS buffer. The molar ratio of envelope to sCD4 in complex experiments was 1:4 with components mixed at room temperature for at least 1 h before analysis. The sensor chip surface was regenerated as above between each cycle.
Deglycosylation of the Trimeric gp140 Proteins-Trimeric gp140 proteins were deglycosylated by endoglycosidase H (Roche Molecular Biochemicals) (1 mg of protein digested by 250 milliunits of endoglycosidase H) at 30°C for 6 h in 50 mM NaAc, pH 6.0, in the presence or absence of Fab fragments of the indicated mAbs. The deglycosylated protein was analyzed by SDS-PAGE and gel filtration chromatography using an analytic Superdex 200 column on an AKTA FPLC (Amersham Pharmacia Biotech).
RESULTS

Stable Expression of Soluble gp140 Protein in CHO-
Lec3.2.8.1 Cell Lines-In order to produce soluble trimeric HIV or HIV/SIV chimeric envelope proteins by recombinant eukaryotic expression, four constructs were made in pEE-14 ( Fig. 1) . A Kozak cassette and tPA leader sequence were introduced into all four constructs 5Ј of the coding sequence of a mature ADA gp120 in order to maximize secreted protein expression from the eukaryotic host. Lec3.2.8.1 cells (39) were chosen as the expression cells to reduce heterogeneity of glycan adducts as discussed below. pEE14-ADA140 contains the entire ADA gp120 protein and the extracellular domain of its gp41 segment, terminating after Lys 632 . A site-directed mutation, Arg 477 to Ser, was introduced in pEE14-ADA140C1 to eliminate the ADA gp120 primary cleavage site and prevent the processing of gp140 into gp120 and gp41. To create a chimeric HIV/SIV gp140 protein, the complete ADA gp120 mature coding sequence was fused with the extracellular domain of the SIV mac32H gp41 coding sequence terminating after Ser 626 . Since trimeric SIV gp140 envelope can be expressed in this system (29), we considered the possibility that if HIV gp140 might be less favorably disposed to form stable trimers, resulting oligomer heterogeneity could be obviated by engineering an SIV gp41 fragment into the chimeric HIV/SIV construct.
Each of the four constructs was transfected into Lec3.2.8.1 cells, and transfectant supernatants were screened by ELISA as described under "Experimental Procedures." Approximately 50% of clones were ELISA-positive. The 10 clones with the highest expression level of soluble gp140 were selected, expanded, and reexamined by ELISA. Cultural supernatants of representative positives were immunoprecipitated by 1A3, and immunoprecipitates were analyzed on SDS-PAGE.
As shown in Fig. 2 (left panel), gp140 ADAC1 and gp140 ADA/SIV proteins produced from both pEE14-ADA140C1-and pEE14-ADA/SIV140-transfected clones, respectively, migrated at about 110 kDa. The theoretical molecular masses of monomeric, nonglycosylated gp140 ADAC1 and gp140 ADA/SIV proteins are each 71 kDa. Since in Lec3.2.8.1 cells, all of the potential N-linked glycosylation sites of the produced protein are modified with simple carbohydrate adducts GlcNAc 2 -Man 5 and there is no O-linked glycosylation modification (39), the predicted molecular masses of monomer gp140 ADAC1 and gp140 ADA/SIV (110 and 108 kDa, respectively) are in close agreement with those observed. In pEE14-ADA140-transfected clones, the recombinant envelope protein was more heterogeneous, with about half running as a 110-kDa band and the other half as a smaller 90-kDa band. The former is uncleaved gp140, whereas the latter is cleaved gp120, as readily appreciated by migration positions of affinity-purified and sized gp140 ADAC1 versus gp120 ADA (Fig. 2, right panel) . These results indicate that the HIV gp140 is sensitive to endogenous proteases in Lec3.2.8.1 cells if both cleavage sites remain native. On the other hand, one single amino acid mutation in the primary cleavage site of the ADA envelope can abolish the protease cleavage of the precursor into gp120 and gp41 fragments in ADA 140C1 transfectants. Surprisingly, in the pEE14-ADA/SIV chimeric construct, the native ADA cleavage sites are intact, yet the chimeric gp140 remains uncleaved. Presumably, the juxtaposition of the GVFVLG sequence (and/or additional sequences) derived from SIV gp41 relative to the AVGTIG sequence of HIV gp41 accounts for this difference (Fig. 1) .
Production and Purification of Soluble gp140 Protein-With the view of obtaining substantial amounts of trimeric envelope protein for structural and biochemical analysis studies, gp140 ADAC1 and gp140 ADA/SIV proteins were expressed at production scale. The resulting supernatants were initially purified by a 1A3 affinity column and further purified by gel filtration chromatography through a Superdex 200 column by FPLC. For both gp140 proteins, the production yield from cell supernatant is about 4 -5 mg/liter following affinity column purification. Due to removal of aggregates, molecular sizing at the subsequent step reduces this yield by one-third. The gel filtration chromatographic profile of affinity-purified and sized protein on the analytic Superdex 200 column (Fig. 3) shows that the majority of both gp140 ADAC1 and gp140 ADA/SIV proteins migrates at the position of ferritin (440 kDa). The elution position of gp140 ADAC1 and gp140 ADA/SIV are 10.21 and 10.31 ml, respectively. A small shoulder migrating at the position of the 669-kDa marker in each chromatograph represents residual protein aggregate. Aside from this, the gel filtration profiles reveal that both gp140 ADAC1 and gp140 ADA/SIV proteins are rather homogeneous with regard to their hydrodynamic volume. SDS-PAGE of proteins from the peak fraction (Fig. 3,  insets) shows only a single band with an apparent molecular mass of 110 kDa. N-terminal amino acid sequence analysis of both gp140 proteins confirmed that the gp140 ADAC1 and gp140 ADA/SIV sequences were correct (both ENLWVTVY). Based upon their gel filtration sizing profiles, the gp140 ADAC1 and gp140 ADA/SIV envelopes expressed in CHO-Lec3.2.8.1 cells are oligomers. ADAC1 and gp140 ADA/SIV by Analytical Ultracentrifugation-To more precisely assess the oligomeric state of gp140 ADAC1 and gp140 ADA/SIV proteins, analytical ultracentrifugation was employed as described under "Experimental Procedures." As shown in Fig. 4 , sedimentation equilibrium data for each envelope fit well into a single-species trimeric model at both speeds for the two gp140 proteins, with no systematic deviations from this model observed. The determined apparent whole-cell weight average molecular weight (M r (app)) of gp140 ADAC1 and gp140 ADA/SIV is 350,000 and 410,000, respectively, indicating that both gp140s are trimeric. The residual data argue for relative homogeneity of the trimeric state of the two gp140 proteins. The difference in apparent molecular weights of trimeric gp140 ADAC1 and gp140 ADA/SIV may be a consequence of slightly more aggregation in the chimeric glycoprotein.
Determination of the Apparent Whole-cell Weight Average Molecular Weight of Soluble gp140
Circular Dichroism Analysis of Envelope Glycoproteins-To investigate the folded state of the envelope glycoproteins, the soluble trimeric gp140 molecules were analyzed by circular dichroism spectrometry, and the data were collected at 25°C. The resulting spectra (Fig. 5) showed similar profiles for gp140 ADAC1 (A) and gp140 ADA/SIV (B) in PBS buffer, indicating FIG. 1. Soluble gp140 constructs. The schematic structure of HIV-1 ADA envelope gp160 precursor protein is shown at the top, including its leader sequence (Leader), gp120 with primary (solid arrowhead) and secondary (open arrowhead) cleavage sites, and gp41 with its fusion peptide (FP), N-terminal helix (N-), C-terminal helix (C-), transmembrane segment (TM), and cytoplasmic tail. The numbering shown begins from the first amino acid residue of the mature gp120. Three gp140 mutants were cloned into the pEE14 vector; all have a Kozak cassette and tPA leader sequence, ADA gp120 coding sequences, and a truncated gp41 segment. In the case of ADA140 and ADA140C1, the latter is after Lys 632 (K632), while for SIV gp41, termination is after Ser 626 (S626). Below ADA gp160 and each ADA mutant are shown amino acid sequences representing the junctional residues of gp120 and gp41. Within this block, the REKR sequence defines the primary cleavage site of ADA gp120, whereas the KAKRR sequence defines the secondary cleavage site of ADA gp120. The amino acid residue immediately C-terminal to the primary cleavage site is the first amino acid of HIV gp41 (ADA140 and ADA140C1) or SIV gp41 (ADA/SIV140). The second line of amino acids below ADA/SIV140 is the amino acid sequence of the SIV gp120/gp41 junction, including its two endogenous cleavage sites. In pEE14-ADA140C1, the primary cleavage site was mutated (from Arg to Ser at residue 477) (S). ADA/SIV140 is a chimera between ADA gp120 and a truncated SIV gp41 segment. ADA gp120 represents the monomeric envelope protein.
FIG. 2. gp140 proteins secreted from CHO-Lec3.2.8.1 cell lines.
The supernatants of Lec3.2.8.1 transfectants representing each of three gp140 constructs were immunoprecipitated by mAb 1A3 bound to GammaBind Plus Sepharose. After washing, bound proteins were eluted by 0.5 M acetic acid, pH 3.0, and analyzed on 10% SDS-PAGE with the gel stained by Coomassie Blue. 7E1 and 9C10 are CHO-Lec3.2.8.1 cell lines of two representative pEE14-ADA/SIV140 transfectants, 4B6 and 5F9 are pEE14-ADA140C1 transfectants, and 3F4 and 3D4 are pEE14-ADA140 transfectants. The positions of molecular weight markers, 1A3 mAb, gp120, and gp140 proteins are indicated. The right panel shows the position of 10 g of affinity-purified and sized gp120 (ADA120) and gp140 (ADA140C1) proteins (lanes 1 and 2) . that both gp140 molecules have comparable secondary structures. A mixture of ␣-helix and ␤-sheet elements apparently exists in each protein, consistent with prior theoretical predictions (45) and indicating that the two proteins are folded. ADAC1 and gp140 ADA/SIV Proteins-To next examine the capacity of the recombinant envelope protein to bind Fab fragments of antibodies that recognize native gp120 or gp41 components, mixing experiments were performed with soluble trimeric gp140 proteins as described under "Experimental Procedures." The resulting complexes were examined by Superdex 200 gel filtration analysis on an AKTA FPLC. As shown in Fig. 6 , A-C, trimeric gp140 ADAC1 can bind 1A3, 16F10, or both 1A3 and 16F10 Fab fragments. These complexes have larger hydrodynamic volumes eluting at V e ϭ 9.64, 9.94, and 9.53 ml, respectively, compared with V e ϭ 10.21 ml for the gp140 alone. SDS-PAGE analysis of peak fractions (Fig. 6, insets) confirms that each of the complexes contains both the gp140 and Fab fragment(s). Due to its chimeric nature, the trimeric gp140 ADA/ SIV protein binds both the 1A3 anti-ADA gp120 (Fig. 6D) and the 9G3 anti-SIV gp41 (Fig. 6E ) Fab fragments, with the individual bimolecular complexes eluting at 9.67 and 9.41 ml, respectively, and the trimolecular complex eluting at 9.04 ml (Fig. 6F) . As expected, the V e of complexes of gp140 ADA/SIV and Fab fragments is increased compared with that of the uncomplexed gp140 ADA/SIV (V e ϭ 10.31 ml). These antibody binding results provide evidence for the native nature of the recombinantly expressed envelope proteins.
Complex Formation and Binding Analysis of mAb Fab Fragments with Glycosylated and Deglycosylated gp140
The HIV envelope proteins are highly glycosylated, with 30 and 29 N-linked sites in gp140 ADAC1 and gp140 ADA/SIV , respectively. Consistent with earlier reports (46) , deglycosylation of N-linked glycans results in exposure of hydrophobic residues, thereby creating insoluble envelope protein. As the Lec3.2.8.1-produced protein is readily deglycosylated by endoglycosidase H, Ͼ95% of the protein is lost even under nondenaturing conditions employing a short incubation period (data not shown). However, for both gp140 ADAC1 and gp140 ADA/SIV envelopes, deglycosylation in the presence of Fabs can prevent a substantial amount of aggregation as shown by gel filtration analysis, despite a 25-kDa reduction in apparent molecular mass on SDS-PAGE (Fig. 6, G-I and insets) . The width of the band corresponding to deglycosylated gp140 in SDS-PAGE suggests that glycan removal is incomplete under native conditions. Note how the ability to rescue the trimeric envelope from aggregation during deglycosylation varies with the antibody used in the complex formation. For example, the V3 loopspecific 1A3 mAb prevents some gp140 ADA/SIV aggregation (Fig.  6H) , whereas the gp41-specific 9G3 mAb Fab fragment is more efficient as judged by the relative amounts of trimeric versus aggregate peaks (Fig. 6I) . To some extent, 1A3 is more effective in rescuing gp140 ADAC1 from aggregation than it is in rescuing gp140 ADA/SIV (Fig. 6, G and H) . Although not shown, gp140 ADAC1 could be rescued by 16F10 Fab alone or in combination with 1A3, while the solubility of gp140 ADA/SIV was improved with the combination of 1A3 plus 9G3. The ability of Fabs in complex with the envelope protein to alter molecular surfaces and preserve solubility may be crucial for successful crystallization efforts using deglycosylated envelope protein.
Kinetics of the Interaction of HIV Envelope Proteins with sCD4 -Since CD4 is the key receptor for HIV envelope-mediated attachment to human T lymphocytes (9, 10), surface plasmon resonance was employed to explore and compare the binding kinetics of sCD4 to trimeric gp140 ADAC1 , trimeric gp140 ADA/SIV , and monomeric gp120 ADA . To this end, the different envelope proteins were immobilized on the sensor chip surface, and then serial dilutions of sCD4 were passed over the immobilized surface. Representative kinetic data from two independent experiments are shown in Fig. 7 and fit well to a 1:1 binding model ( 2 Ͻ 10). The gp120 ADA -sCD4, gp140 ADAC1 -sCD4, and gp140 ADA/SIV -sCD4 all display similar k on and k off rates with their K D values in the 1-2 nM range (Fig. 7) . Hence, the affinity of the trimeric HIV gp140 for sCD4 is comparable with that of the monomeric gp120 species. Note that the gp140 SIV-sCD4 interaction, as determined previously, 3 is 100-fold weaker, primarily as a result of the much slower k on and a somewhat faster k off (Fig. 7D) . ADAC1 and gp140 ADA/SIV with Fab fragments. 100 g of gel filtration-purified gp140 trimers in PBS were incubated at 1:4 molar ratio with their Fab fragments (1A3 and 16F10 for gp140 ADAC1 , 1A3 and 9G3 for gp140 ADA/SIV , respectively) at 4°C for 2 h. The complexes and the excess Fab fragments were separated by a Superdex 200 analytic column using an AKTA FPLC. The peak fractions were collected, concentrated, and analyzed by 10% SDS-PAGE and Coomassie staining of gels (insets). Within each inset in A-F, the first lane represents protein from the complex peak, and in B-E, the second lane represents the excess Fab fragment(s) as collected from the later eluting, minor peak. A-C show the complexes between 1A3, 16F10, or 1A3 plus 16F10 Fab fragments and gp140 ADAC1 ; D-F show the complexes between 1A3, 9G3, or 1A3 plus 9G3 Fab fragments and gp140 ADA/SIV . In G-I in the third row, results of envelope deglycosylation experiments are shown. 100 g of both purified gp140 trimers were mixed with Fab fragments and incubated with endoglycosidase H for 6 h at 30°C. Any precipitates were removed by centrifugation, and remaining soluble protein was then analyzed by Superdex 200 gel filtration chromatography. The peaks of soluble deglycosylated (Dgp140) complex (indicated by arrows) were pooled, and the concentrated proteins were analyzed by 10% SDS-PAGE. Lane 1 in the insets represents the nondeglycosylated gp140 for comparison. G represents gp140 ADAC1 deglycosylated in the presence of 1A3, and H and I represent gp140 ADA/SIV deglycosylated in the presence of 1A3 and 9G3 Fab fragments, respectively.
Trimeric Recombinant Envelope Proteins are Conformationally Altered by sCD4 -A human neutralizing mAb, 17b, which defines an epitope overlapping the co-receptor CCR5 binding domain (44, 47, 48) , binds HIV gp120 proteins with higher affinity upon CD4-induced conformational change (49 -54) . To examine whether the trimeric ADA gp140 proteins are capable of undergoing such a structural change, surface plasmon resonance was employed to measure binding affinities between 17b and trimeric gp140 in the presence or absence of sCD4 and compared with similarly treated ADA gp120. To this end, 17b mAb was immobilized on the biosensor chip surface, and serial dilutions of the envelope proteins with or without sCD4 were passed through in the analyte. As shown in Fig. 8 , at the same concentration, all three envelope proteins have a much higher binding on rate when precontacted by sCD4. Although the dissociation rate of all three envelope proteins (with or without sCD4) are too slow to accurately measure, the k on rates can be readily ascertained and are increased dramatically upon CD4 interaction with the envelope protein. The k on of gp120 ADA with sCD4 increased 4.8 times compared with gp120 ADA itself (9.14 ϫ 10 Ϫ1 s Ϫ1 ). These data indicate that both trimers undergo significant conformational change induced by sCD4, resulting in expression of the 17b epitope. Collectively, the results suggest that the gp140 trimers further expose their chemokine receptor binding site following CD4 interaction, although the gp120 and gp41 subunits remain covalently linked in these trimeric precursors. This result provides further support for the notion that the recombinant envelope gp140 protein is native.
DISCUSSION
In the present study, we have produced soluble, trimeric HIV envelope ectodomain proteins using recombinant expression in Lec3.2.8.1 cells. Envelope yields after affinity purification are 4 -5 mg/liter for either ADA (gp140 ADAC1 ) or an ADA/SIV chimera (gp140 ADA/SIV ), which fuses ADA gp120 and SIV gp41 ectodomain segments. Native conformation of the recombinant envelopes was ascertained by several criteria. First, Superdex gel filtration chromatography and analytical ultracentrifugation both show that the envelopes are oligomers, with the latter defining a trimeric state. Second, CD spectra of the proteins show clear evidence for secondary structure elements, consistent with a folded state. Third, conformation-dependent mAbs to native spike epitopes react with the secreted envelope protein, as does CD4, the latter being the cellular receptor for HIV binding.
Because others found expression of HIV envelope trimers to be difficult (7, 22, 24, 55) , we employed a strategy of linking ADA gp120 to SIV mac32H gp41 extracellular segments, since our previous studies indicated that SIV gp140 trimers were readily produced in the Lec3.2.8.1 system (29) . Both chimeric and nonchimeric proteins were secreted as oligomers so long as the primary and secondary sites were not cleaved. In this regard, prior studies indicated that mutations of one or both cleavage sites in HIV or SIV envelopes can abolish processing of the gp160 precursor to gp120 and gp41 subunits (19, 20, 56) . Surprisingly, for gp140 ADA/SIV protein, despite preservation of the native cleavage site in the ADA gp120 moiety, the resultant protein remained uncleaved. This finding suggests that the amino acid sequences around the cleavage site also contribute to processing. Given that ADA gp120 protein is monomeric (consistent with the other gp120 proteins examined to date (see Ref. 15 and references therein; data not shown)), these results document that the gp41 segment is necessary and sufficient for the trimeric oligomerization of the envelope. The HIV and SIV gp41 ectodomain segments are virtually structurally identical as elucidated crystallographically (30, 31, 33, 34) . Both proteins possess a core N-terminal helical trimer against which an anti-parallel C-terminal helix trimer packs. This produces a six-helix bundle and is consistent with the interchangeability of the HIV and SIV gp41 fragments. Such HIV/SIV gp41 substitution does not perturb the CD4 binding function or anti-ADA gp120 mAb reactivities examined herein.
Production of stable trimeric gp140 in earlier reports required introduction of disulfide bonds between gp120 and gp41 subunits with or without a GCN4 leucine zipper (27, 28, 57) . No such additions were required in the present study. While it is possible that sequence variation due to different strain origins of the envelopes may be responsible, at least in part, for their different behaviors, isolation and/or protein handling differences may also be contributory. For example, sucrose density gradient centrifugation methods and attendant buffer conditions may perturb oligomerization. It is also possible that differences in glycosylation among production cell lines alter the behavior of the resultant envelope proteins. Until comparison is made of the same envelopes from different production lines employing a matrix of purification strategies, the basis of these differences remains conjectural.
As each gp140 envelope trimer is heavily glycosylated (ϳ90 N-linked sites per molecule), the glycan adducts are a major source of heterogeneity. The homogeneous adducts (GlcNAc 2 -Man 5 ) produced in the Lec3.2.8.1 cell line reduce this complexity. While both gp140 ADAC1 and gp140 ADA/SIV can be deglycosylated by endoglycosidase H to a size approximating that of the core protein, such a deglycosylated product is insoluble, requiring complex formation with one or more Fab envelope fragments to maintain solubility. This approach may be useful for future crystallization efforts.
The interactions of sCD4 with gp120 ADA , gp140 ADAC1 , and gp140 ADA/SIV were all comparable with a 1-2 nM K D . These data are consistent with those reported for previously determined CD4-HIV gp120 protein interactions including YU2 gp120 (2.2 and 1.9 nM), 89.6 gp120 (2.7 nM), HXB2 gp120 (6.5 nM), JRFL gp120 (28 nM), and BH-10 gp120 (2-20 nM) (53, 58, 59) . Cell-bound trimeric gp160 HB08-CD4 affinity was reported to be weaker than that of the monomeric HB08 gp120-CD4 interaction (25) . Whether this difference relates to other cellular factors affecting affinity measurement is currently uncertain. Most interesting, however, is the contrast between sCD4 binding affinity values obtained with SIV mac32H gp120 versus SIV mac32H gp140 and those reported herein for ADA using equivalent surface plasmon resonance methodology and the same Lec3.2.8.1 cell host for protein expression. Unlike with HIV, SIV gp120 manifests a stronger sCD4 binding affinity than its trimeric SIV gp140 counterpart (52-71 versus 190 -210 nM). Moreover, this anticooperativity is manifest as an inability of the SIV gp140 trimer to bind more than one sCD4 molecule, despite displaying three equivalent CD4 binding sites. 3 In the case of HIV, more than one CD4 binding site per trimer envelope has been functionally documented using differential CD4 binding assays (22) . The BIAcore analysis herein is also consistent with a lack of anticooperativity effect for the ADA HIV gp140 trimer.
How might such a difference be explained? The HIV glycoprotein envelope exists in a series of conformational states: an unligated state found on the surface of intact virions, a CD4-ligated intermediate state, and an end product state in which the gp120 fragment has dissociated from the gp41 trimer with attendant gp41 segment rearrangement (49, 50, 60) . The transition to this last state requires binding of the viral co-receptor, a member of the chemokine receptor family (13, 61) . In this regard, it is possible that recombinant SIV mac32H gp140 exists in a tightly configured pre-CD4 contacted state. Hence, any sCD4 contact may require in addition substantial conformational change to induce subsequent transition. By contrast, the ground state of the ADA gp140 protein may be more "open" so that CD4 binding sites on each gp120 protomer within a spike are independent, individually capable of binding sCD4 without requiring major conformational alterations to achieve binding. If this notion is correct, then the HIV envelope may be more further evolved toward the "fusion-ready" transition than SIV. In this regard, it is already evident that there are differences between HIV and SIV insofar as chemokine receptor binding site exposure (42, 44, 62) . Whether this postulated difference between HIV and SIV is true for this comparison alone or indicative of differences in HIV and SIV strains in general remains to be determined. Whatever the case, given that gp140 ADAC1 and gp140 ADA/SIV show similar binding characteristics, the behavior of these ADA-derived HIV envelopes versus SIV gp140 mac32H must be due to differences within their gp120 moieties. SIV gp120 may produce stronger SIV gp120-SIV gp120 protomer contacts within a trimer than the corresponding HIV gp120-HIV gp120 subunit contacts in an ADA envelope spike.
The fidelity of the recombinant envelope protein structure to that of the viral spike is suggested both by the sCD4 binding and mAb analysis. In further support of this notion, sCD4 binding induces enhanced 17b binding by gp140 ADAC1 and gp140 ADA/SIV , implying that conformational changes in V1V2 and perhaps elsewhere expose the chemokine receptor binding area as observed for viral gp120 (44, 51) . Given that this conformational transition of the gp140 precursors studied here proceeds in the absence of gp120-gp41 cleavage, deletion of primary and secondary processing sites may inhibit viral infectivity (19, 20) by preventing subsequent conformational transitions. Those downstream alterations will expose a fusion peptide probably sequestered within a buried axial groove as configured in the resting, pre-CD4/prechemokine receptor bound state. With utilization of recombinant proteins such as these as substrates for probing retroviral envelope function, additional insights into the molecular basis of viral attachment and fusion should be possible. Moreover, these proteins should also be useful for understanding HIV envelope immunogenicity and, ultimately, its three-dimensional structure.
